未经证实:糖尿病在CF(PwCF)患者中普遍存在,并与较差的临床结局相关。CFTR调节剂在改善CF的病程方面非常有效。然而,elexacaftor/tezacaftor/ivacaftor(ETI)对PwCF中葡萄糖代谢的影响尚不清楚。
未经证实:20名患有CF的青年和成年人在ETI开始之前和之后接受了频繁采样的口服葡萄糖耐量试验(fsOGTT)。葡萄糖,胰岛素,在1.75g/kg(最大75g)右旋糖后0、10、30、60、90和120分钟收集C-肽。在一个子集中收集HbA1c和连续葡萄糖监测(CGM)。胰岛素分泌的估计(C肽指数),胰岛素抵抗(HOMA2IR和IS(OGTTCpep)),和β细胞功能(C肽口服处置指数,oDIcoeo),在ETI之前和之后进行了比较。
未经评估:参与者的年龄中位数(IQR)为20.4(14.1,28.6)岁,75%男性。ETI开始后10.5(10.0,12.3)个月进行随访。BMIz分数从0.3(-0.3,0.8)增加到0.8(0.4,1.5),两次访问之间p=0.013。在葡萄糖耐量方面没有观察到显著差异,曲线下的葡萄糖面积,ETI前后的fsOGTT葡萄糖浓度也没有。中位数(IQR)C肽指数从5.7(4.1,8.3)增加到8.8(5.5,10.8)p=0.013,HOMA2IR增加(p<0.001),而oDIcoeo没有变化(p=0.67)。HbA1c从5.5%(5.5,5.8)下降到5.4%(5.2,5.6)(p=0.003),而CGM变量没有变化。
UNASSIGNED:BMIz评分和胰岛素抵抗和胰岛素分泌的测量在ETI开始的第一年内增加。根据胰岛素敏感性(oDIcoeo)调整的β细胞功能没有变化。
UNASSIGNED: Diabetes is prevalent among people with CF (PwCF) and associated with worse clinical outcomes. CFTR modulators are highly effective in improving the disease course of CF. However, the effects of elexacaftor/tezacaftor/ivacaftor (ETI) on glucose metabolism in PwCF are unclear.
UNASSIGNED: Twenty youth and adults with CF underwent frequently sampled oral glucose tolerance tests (fsOGTT) before and after ETI initiation. Glucose, insulin, and C-peptide were collected at 0, 10, 30, 60, 90, and 120 min after 1.75 g/kg (max 75 g) of dextrose. HbA1c and continuous glucose monitoring (CGM) were collected in a subset. Estimates of insulin secretion (C-peptide index), insulin resistance (HOMA2 IR and IS(OGTT Cpep)), and β-cell function (C-peptide oral disposition index, oDIcoeo), were compared before and after ETI.
UNASSIGNED: Participants were a median (IQR) of 20.4 (14.1, 28.6) years old, 75 % male. Follow-up occurred 10.5 (10.0, 12.3) months after ETI initiation. BMI z-score increased from 0.3 (-0.3, 0.8) to 0.8 (0.4, 1.5), p = 0.013 between visits. No significant differences were observed in glucose tolerance, glucose area under the curve, nor fsOGTT glucose concentrations before and after ETI. Median (IQR) C-peptide index increased from 5.7 (4.1, 8.3) to 8.8 (5.5, 10.8) p = 0.013 and HOMA2 IR increased (p < 0.001), while oDIcoeo was unchanged (p = 0.67). HbA1c decreased from 5.5 % (5.5, 5.8) to 5.4 % (5.2, 5.6) (p = 0.003) while CGM variables did not change.
UNASSIGNED: BMI z-score and measures of both insulin resistance and insulin secretion increased within the first year of ETI initiation. β-cell function adjusted for insulin sensitivity (oDIcoeo) did not change.